It's a gamechanger29 Mar 2018 16:59
"We believe C4X's OX1 program is one of the most promising early-stage programs to potentially treat addiction and look forward to rapidly advancing lead compound C4X3256 into the clinic," said Christian Heidbreder, chief scientific officer of Indivior. "Further, we believe there is great potential for additional compounds to be discovered and developed with respect to this important mechanism that will contribute to the continued elucidation of the neurobiological underpinnings of withdrawal symptoms, drug intake, craving, relapse, and co-morbid psychiatric associations," he noted.